Breadcrumbs

Neurological - oncology

Protocol Administration at chemotherapy unit level Review date
Anaplastic glioma PCV (procarbazine lomustine vinCRISTine) Medium September 2022
Anaplastic glioma temozolomide following radiation Low March 2021
Glioblastoma recurrent bevacizumab Low March 2021
Glioblastoma recurrent lomustine Low December 2021
Glioblastoma temozolomide chemoradiation (part 1) Low 3 September 2020
Glioblastoma temozolomide following chemoradiation (part 2) Low September 2020
Glioblastoma temozolomide short course chemoradiation (elderly patients) (part 1) Low 3 March 2021
Glioblastoma temozolomide following short course chemoradiation (elderly patients) (part 2) Low March 2021
Glioma high grade or recurrent temozolomide Low March 2021
Glioma high grade recurrent PCV (procarbazine lomustine vinCRISTine) Medium September 2022
Glioma low grade PCV (procarbazine lomustine vinCRISTine) Medium September 2022

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Local radiotherapy services required
  4. Non-formulary drug included in the protocol
  5. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

^ Back to top